GRIMES & Co WEALTH MANAGEMENT LLC Sells 28,024 Shares of Bristol Myers Squibb Company $BMY

GRIMES & Co WEALTH MANAGEMENT LLC lessened its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 7.5% in the 4th quarter, HoldingsChannel.com reports. The firm owned 347,619 shares of the biopharmaceutical company’s stock after selling 28,024 shares during the quarter. GRIMES & Co WEALTH MANAGEMENT LLC’s holdings in Bristol Myers Squibb were worth $18,751,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Physician Wealth Advisors Inc. grew its stake in Bristol Myers Squibb by 73.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 202 shares during the last quarter. Darwin Wealth Management LLC purchased a new position in Bristol Myers Squibb during the 2nd quarter worth $25,000. EQ Wealth Advisors LLC purchased a new position in Bristol Myers Squibb during the 4th quarter worth $32,000. Garner Asset Management Corp purchased a new position in Bristol Myers Squibb during the 4th quarter worth $35,000. Finally, Beacon Financial Strategies CORP purchased a new position in Bristol Myers Squibb during the 4th quarter worth $38,000. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of the company’s stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total value of $1,850,100.00. Following the sale, the executive vice president directly owned 159,248 shares of the company’s stock, valued at approximately $9,820,824.16. This represents a 15.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.05% of the company’s stock.

Bristol Myers Squibb Trading Down 0.7%

Shares of Bristol Myers Squibb stock opened at $56.18 on Friday. The stock has a market cap of $114.73 billion, a PE ratio of 15.78, a price-to-earnings-growth ratio of 0.16 and a beta of 0.26. The firm has a fifty day moving average price of $59.28 and a 200 day moving average price of $54.91. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $62.89. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.42 and a quick ratio of 1.28.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The company had revenue of $11.49 billion for the quarter, compared to analyst estimates of $10.93 billion. During the same period in the prior year, the company earned $1.80 earnings per share. The firm’s revenue was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities research analysts predict that Bristol Myers Squibb Company will post 6.29 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd were issued a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 4.5%. The ex-dividend date of this dividend was Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio is presently 70.79%.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on BMY shares. Wall Street Zen upgraded shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Sunday, April 19th. HSBC upped their price target on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the company a “hold” rating in a research note on Tuesday, March 17th. Wells Fargo & Company restated an “outperform” rating and set a $60.00 price target (up from $55.00) on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Leerink Partners upped their price target on shares of Bristol Myers Squibb from $54.00 to $60.00 and gave the company an “outperform” rating in a research note on Tuesday, January 13th. Finally, Royal Bank Of Canada started coverage on shares of Bristol Myers Squibb in a research note on Tuesday, February 24th. They set a “sector perform” rating and a $60.00 price target on the stock. Eight analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $61.31.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Zacks (covered on Yahoo Finance) highlights BMY as a top value stock for long?term investors, emphasizing attractive style scores and dividend appeal that support buy?and?hold interest. Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term
• Positive Sentiment: BMY is named in reports about BioNTech expanding pivotal oncology trials done in collaboration with Bristol Myers Squibb—this pipeline activity can boost long?term revenue potential if trials progress. BioNTech Expands Oncology Trials And Reshapes Manufacturing As Investors Weigh Upside
• Positive Sentiment: BMY will participate at the Bank of America Securities Healthcare Conference, giving management a forum to reinforce guidance, pipeline timelines and commercialization plans—an opportunity to reassure investors. Bristol Myers Squibb to Participate in the Bank of America Securities Healthcare Conference 2026
• Neutral Sentiment: BMY launched a nationwide “Won’t Lose” World Cup?focused patient campaign to raise brand awareness; marketing may aid long?term patient engagement but has limited immediate earnings impact. Bristol Myers Squibb World Cup Push Meets Valuation And Earnings Questions
• Neutral Sentiment: Analysts’ Q1 call questions (MSN recap) show market attention on growth drivers and margin dynamics—such scrutiny can amplify short?term volatility even when fundamentals are intact. Bristol-Myers Squibb’s Q1 earnings call: Our top 5 analyst questions
• Neutral Sentiment: Commentary questioning whether BMY still offers value after a ~25% one?year share gain highlights investor debate over valuation vs. yield; this may encourage profit taking. Is Bristol Myers Squibb (BMY) Offering Value After A 25.7% One Year Share Price Gain

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.